Kicking off the COMBO project
Targeting the pharmaceutical sector holds great potential for seaweed cultivation in Europe and the USA
According to Prof. Olivier Thomas, a marine biodiscovery researcher from the University of Galway, there is currently a discrepancy between the species that can be cultivated and the species that interest the pharmaceutical sector. Therefore, research is needed on how to cultivate species that have never been domesticated. Think about it like the early forms of the grains we now eat, which used to look more like grass. The level of cultivation of these seaweed species is still at this level.
Promising seaweed species for this project are Laurencia pinnatifida and Dictyota dichotoma, as they are rich in a group of bioactive compounds called terpenes

The target species Laurencia pinnatifida and Dictyota dichotoma are found all over the world

Land-based cultivation systems are especially suitable to reach the quality desired by the pharmaceutical industry
Therefore, we’ll be working closely with Mungo Murphy’s Seaweed Company in Ireland to prepare their land-based aquaculture facilities. Cultivating seaweed in combination with the established abalone cultivation would allow them to return the seawater cleaner than it entered the system.
The possibilities of OMICS technology to speed up the domestication of seaweed species seem endless
Seaweed also has millions of years of evolution together with microbes, and their interdependency seems to be a rule rather than an exception
